Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

New Trends in Allergy and Atopic Eczema

Editor(s): Ring J. (Munich) 
Darsow U. (Munich) 
Behrendt H. (Munich) 
Cover

Clinical Aspects

Bone Mineral Density in Patients with Atopic Dermatitis

Haeck I. · van Velsen S. · de Bruin-Weller M. · Bruijnzeel-Koomen C.

Author affiliations

Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands

Related Articles for ""

Ring J, Darsow U, Behrendt H (eds): New Trends in Allergy and Atopic Eczema. Chem Immunol Allergy. Basel, Karger, 2012, vol 96, pp 96–99

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Clinical Aspects

Published online: March 13, 2012
Cover Date: 2012

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-8055-9894-1 (Print)
eISBN: 978-3-8055-9895-8 (Online)

Abstract

In a recent investigation of bone mineral density (BMD) in patients with moderate-to-severe AD, we found that one third of the patients had a low BMD, predominately males. This could be due to the use of topical corticosteroids or due to chronic inflammation. However, neither could be held responsible for the above finding. Low BMD at baseline does not seem to progress quickly, as assessed in a 2-year follow-up study. Treatment of low BMD is questionable as the effect of vitamin D and/or calcium supplementation on low BMD is controversial. We recommend performing long-term follow-up studies to assess the course of BMD over time from onset of AD.

© 2012 S. Karger AG, Basel


References

  1. Haeck I, Hamdy N, Timmer-de Mik L, Lentjes E, Verhaar H, Knol M, de Bruin-Weller M, Bruijnzeel-Koomen C: Low bone mineral density in adult patients with moderate to severe atopic dermatitis. Br J Dermatol 2009;161:1248-1254
  2. Pietschmann P, Rauner M, Sipos W, Kerschan-Schindl K: Osteoporosis: an age-related and genderspecific disease - a mini-review. Gerontology 2009;55:3-12
  3. Aalto-Korte K, Turpeinen M: Bone mineral density in patients with atopic dermatitis. Br J Dermatol 1997;136:172-175
  4. Munro DD: The effect of percutaneously absorbed steroids on hypothalamic-pituitary-adrenal function after intensive use in in-patients. Br J Dermatol 1976;94:((suppl 12))67-76
  5. Munro DD: Topical corticosteroid therapy and its effect on the hypothalamic-pituitary-adrenal axis. Dermatologica 1976;152:((suppl 1))173-180
  6. Weston WL, Fennessey PV, Morelli J, Schwab H, Mooney J, Samson C, et al: Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent topical steroids by standard endocrine function testing and gas chromatographic mass spectrometry. J Invest Dermatol 1988;90:532-535
  7. Hehir M, Du VA, Eilon L, Danie MJ, Shenoy EV: Investigation of the pharmacokinetics of clobetasol propionate and clobetasone butyrate after a single application of ointment. Clin Exp Dermatol 1983;8:143-151
  8. Pariser D: Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption. Am J Ther 2009;16:264-273
  9. van Velsen S, Haeck I, Knol M, Lam M, Bruijnzeel-Koomen C: Two-year follow-up of bone mineral density in adults with moderate to severe atopic dermatitis: no effect of topical cortcosteroids. J Am Acad Dermatol 2010;63:824-831
  10. Farmacotherapeutisch Kompas 2009 The Netherlands. http://www.farmacotherapeutischkompas.nl (accessed December 2009)
  11. Zuberbier T, Orlow SJ, Paller AS, Taieb A, Allen R, Hernanz-Hermosa JM, et al: Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006;118:226-232
  12. Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van't Hof MA, Lemmens JA: Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993;119:963-968
  13. Rizzato G, Montemurro L: Reversibility of exogenous corticosteroid-induced bone loss. Eur Respir J 1993;6:116-119
  14. LoCascio V, Ballanti P, Milani S, Bertoldo F, LoCascio C, Zanolin EM, et al: A histomorphometric long-term longitudinal study of trabecular bone loss in glucocorticoid-treated patients: prednisone versus deflazacort. Calcif Tissue Int 1998;62:199-204
  15. Saito JK, Davis JW, Wasnich RD, Ross PD: Users of low-dose glucocorticoids have increased bone loss rates: a longitudinal study. Calcif Tissue Int 1995;57:115-119
  16. Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Ines LB, et al: Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006;65:285-293
  17. Walsh NC, Crotti TN, Goldring SR, Gravallese EM: Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005;208:228-251
  18. Clowes JA, Riggs BL, Khosla S: The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev 2005;208:207-227
  19. Isenor JE, Ensom MH: Is there a role for therapeutic drug monitoring of vitamin D level as a surrogate marker for fracture risk?. Pharmacotherapy 2010;30:254-264
  20. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM: Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;125:961-968
  21. Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S, Sebaldt RJ, et al: Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year follow-up. J Rheumatol 1996;23:995-1000
  22. Compston J: Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol 2010;6:82-88

Article / Publication Details

First-Page Preview
Abstract of Clinical Aspects

Published online: March 13, 2012
Cover Date: 2012

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-8055-9894-1 (Print)
eISBN: 978-3-8055-9895-8 (Online)


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.